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Abstract
Background Agomelatine is a melatonin receptor agonist and serotonin 5-HT2C receptor antagonist indicated for depression 
in adults. Hepatotoxic reactions like acute liver injury (ALI) are an identified risk in the European risk management plan for 
agomelatine. Hepatotoxic reactions have been reported for other antidepressants, but population studies quantifying these 
risks are scarce. Antidepressants are widely prescribed, and users often have risk factors for ALI (e.g. metabolic syndrome).
Objective The goal was to estimate the risk of ALI associated with agomelatine and other antidepressants (fluoxetine, par-
oxetine, sertraline, escitalopram, mirtazapine, venlafaxine, duloxetine, and amitriptyline) when compared with citalopram 
in routine clinical practice.
Method A nested case–control study was conducted using data sources in Denmark, Germany, Spain, and Sweden (study 
period 2009–2014). Three ALI endpoints were defined using International Classification of Diseases (ICD) codes: primary 
(specific codes) and secondary (all codes) endpoints used only hospital discharge codes; the tertiary endpoint included both 
inpatient and outpatient settings (all codes). Validation of endpoints was implemented. Adjusted odds ratios (ORs) and 95% 
confidence intervals (CIs) for current use were estimated for each data source and combined.
Results We evaluated 3,238,495 new antidepressant and 74,440 agomelatine users. For the primary endpoint, the OR for 
agomelatine versus citalopram was 0.48 (CI 0.13–1.71). Results were also < 1 when no exclusion criteria were applied (OR 
0.37; CI 0.19–0.74), when all exclusion criteria except alcohol and drug abuse were applied (OR 0.47; CI 0.20–1.07), and 
for the secondary (OR 0.40; CI 0.05–3.11) and tertiary (OR 0.79; CI 0.50–1.25) endpoints. Regarding other antidepressants 
versus citalopram, most OR point estimates were also below one, although with varying widths of the 95% CIs. The result 
of the tertiary endpoint and the sensitivity analyses of the primary endpoint were the most precise.
Conclusion In this study, using citalopram as a comparator, agomelatine was not associated with an increased risk of ALI 
hospitalisation. The results for agomelatine should be interpreted in the context of the European risk minimisation measures 
in place. Those measures may have induced selective prescribing and could explain the lower risk of ALI for agomelatine 
when compared with citalopram. Most other antidepressants evaluated had ORs suggesting a lower risk than citalopram, 
but additional studies are required to confirm or refute these results.
The study protocol was registered in the European Medicines 
Agency electronic Register of Post-Authorisation Studies (EU PAS 
Register # EUPAS10446).
Dr. Castellsagué is now retired.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 3-019-00611 -9) contains 
supplementary material, which is available to authorized users.
Extended author information available on the last page of the article
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Key Points 
Agomelatine did not increase the risk of hospitalisation 
due to acute liver injury (ALI) in the studied populations 
when compared to citalopram. Results were robust in 
multiple sensitivity analyses.
In the populations studied, risk minimisation measures 
were in place and may have contributed to the lower risk 
found for agomelatine when compared with citalopram. 
Thus, compliance with relevant contra-indications, 
precautions of use, and biological liver testing before and 
during treatment are still required to prescribe agomela-
tine.
Of the other antidepressants, sertraline, escitalopram, 
mirtazapine, venlafaxine, duloxetine, and amitriptyline 
had a lower risk of ALI hospitalisation when compared 
to citalopram.
1  Background
Agomelatine (Valdoxan, Thymanax) is a melatonin receptor 
agonist and serotonin 5-HT2C antagonist indicated for major 
depressive episodes in adults [1]. Hepatotoxic reactions are 
an identified risk of agomelatine included in the European 
risk management plan and the drug label, which recommend 
that aminotransferase levels are checked before treatment 
initiation and then after 3, 6, 12, and 24 weeks and following 
a dose increase [2]. While other antidepressant drugs used 
in Europe do not have similar recommendations, hepato-
toxic reactions do occur with some of them. The severity and 
frequency of those reactions vary among antidepressants. 
According to studies based only on case reports, they seem 
to be more common and severe with use of tricyclic antide-
pressants and monoamine oxidase inhibitors than with use 
of serotonin norepinephrine reuptake inhibitors and selective 
serotonin reuptake inhibitors (0.5–1%) [3, 4]. Acute liver 
injury (ALI) refers to the sudden appearance of liver test 
abnormalities and encompasses a spectrum of clinical dis-
eases ranging from mild biochemical abnormalities to acute 
liver failure [5]. When known causes of ALI have been ruled 
out and criteria for causality of a specific drug are met, the 
term drug-induced liver injury is used instead [5, 6]. Stand-
ardised definitions of ALI for use in epidemiological studies 
have been proposed [5, 7], and the incidence of ALI related 
to antidepressant use requiring hospitalisation has been esti-
mated to be one to four cases per 100,000 patient-years [3].
Antidepressant drugs are currently among the most 
widely used drugs in Western countries [8, 9], and often 
patients using them have risk factors for ALI, such as alcohol 
and drug abuse and dependence, and metabolic syndrome 
[10–12]. Other risk factors for ALI include older age, female 
sex, concurrent use of hepatotoxic medications, previous 
acute and chronic hepatic, biliary, and pancreatic conditions, 
malnutrition, HIV infection, and chronic inflammatory dis-
eases [13, 14].
Two previous studies on the risk of ALI associated with 
the use of duloxetine have been conducted using Ingenix 
Research Data Mart and the Optum Research Database in 
the United States [15, 16], suggesting an increased risk of 
ALI with duloxetine when compared with venlafaxine [15, 
16] and selective serotonin reuptake inhibitors [15].
The primary goal of this post-authorisation safety study 
[17], using a nested case–control analysis, was to evaluate 
the risk of hospitalisation for ALI associated with agomela-
tine and eight other antidepressant drugs as used in current 
medical practice compared with citalopram.
2  Methods
2.1  Study Design and Study Period
In brief, we conducted a large, multinational, retrospective 
longitudinal cohort and nested case–control study compar-
ing new users of agomelatine (main exposure of interest) 
and new users of eight other study antidepressants with new 
users of citalopram (common reference group). Citalopram 
was selected as a comparator because it was the most com-
monly used antidepressant in three of the four countries 
and, according to literature reviews available at the time of 
writing the protocol, was among the antidepressants with 
the least potential for hepatotoxicity [3, 4]. The other anti-
depressants were selected because they were commonly 
used across all countries. The study period in each data 
source started after the launch of agomelatine in the respec-
tive country (in 2009 or 2010) and ended with the last year 
for which data were available in each data source (2013 or 
2014). The full study protocol can be accessed at the Euro-
pean Union Electronic Register of Post-Authorisation Stud-
ies (EU PAS Register # EUPAS10446) [18].
2.2  Setting
This study was conducted in automated health databases 
in four countries: Spain (SIDIAP [Information System 
for Research in Primary Care] [19] and EpiChron Cohort 
[EpiChron Research Group on Chronic Diseases] [20]), 
Germany (GePaRD [German Pharmacoepidemiological 
Research Database]) [21–23] and Denmark [24–29] and 
Sweden [29–31] (using their national registers). Character-
istics of the databases are described in Online Resource 1 
(see the electronic supplementary material).
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2.3  Study Population
The study cohort included all individuals aged 18 years or 
older at the date of the first-recorded prescription fill of any 
of the study antidepressants during the study period(s) who 
(1) had not received a prescription fill for the same study 
antidepressant within the prior 12 months (new users) and 
(2) had at least 12 months of continuous enrolment in the 
data source before the first prescription fill defining cohort 
entry. Thus, one patient could contribute to several anti-
depressant cohorts if eligibility criteria were fulfilled. For 
women, an additional eligibility criterion was absence of 
pregnancy at the start date of antidepressant use. Patients 
with a history of liver disease or risk factors for liver disease 
(e.g. alcohol and drug abuse and dependence-related disor-
ders), chronic biliary or pancreatic disease, malignancy, or 
other life-threatening conditions (e.g. cancer, HIV infection) 
were excluded from the study cohort (see Online Resource 
2 in the electronic supplementary material for a detailed list 
of exclusion criteria).
2.4  Endpoints Ascertainment: Selection of Cases 
and Controls
The primary endpoint was ascertained in all data sources 
and defined as any patient with a specific hospital discharge 
diagnosis code of ALI from either the International Clas-
sification of Diseases, 9th Revision (ICD-9) or the Inter-
national Statistical Classification of Diseases and Related 
Health Problems, 10th Revision (ICD-10).
The secondary endpoint was defined as validated cases 
of ALI (see below) identified with specific and nonspecific1 
hospital discharge diagnosis codes and was evaluated only 
in Spain (EpiChron and SIDIAP) and Denmark.
The exploratory tertiary endpoint was assessed based on 
specific and nonspecific codes identified in both hospital 
and outpatient settings and was evaluated in all data sources 
regardless of whether validation was feasible. A sensitivity 
analysis restricted to validated cases was conducted in the 
three data sources in which validation was implemented. The 
list of specific and nonspecific codes is included in the elec-
tronic supplementary material (Online Resource 3). The list 
of codes was adapted to the country-specific ICD classifica-
tion system used. The investigators in each country reviewed 
the codes list and made small adaptations when necessary. 
Additionally, local clinicians were consulted.
Potential cases of ALI identified with specific and non-
specific codes were confirmed by validation processes 
according to the definition criteria established by an inter-
national expert working group [5]. The definition criteria 
are based on increases in the levels of alanine aminotrans-
ferase (ALT), alkaline phosphatase (ALP), and bilirubin over 
the upper limit of normality (ULN) with less than 1 year 
of persistence: (≥ 5 × ULN ALT) or (≥ 2 × ULN ALP) or 
(≥ 3 × ULN ALT and > 2 × ULN bilirubin). This study was 
not designed to evaluate causality at the individual level to 
ascertain whether a specific case with phenotypical ALI 
had drug-induced liver injury or not. Rather, the study was 
designed to examine the potential causal role of agomelatine 
and other antidepressants when compared with citalopram 
in the development of ALI at the population level. Thus, 
no formal evaluations using the Roussel Uclaf Causality 
Assessment Method (RUCAM) [32] were implemented at 
the individual case level. Potential cases were adjudicated by 
trained clinicians based on review of information abstracted 
from medical records. This information included timing 
and results of liver enzymes and information on presence 
or absence of excluding conditions [33]. Thus, the clinical 
reviewers were adjudicating whether the individual potential 
cases met the study definition criteria of ALI and whether 
excluding conditions were present, not whether they met 
criteria for causality between antidepressant use and liver 
injury. Validity of the electronic algorithms based on diag-
nosis codes used in the secondary and tertiary endpoints was 
assessed by calculating the positive predictive value (PPV), 
defined as the probability that a patient classified as a poten-
tial case was a confirmed case of ALI based on the reviewed 
data (excluding nonevaluable cases from the denominator).
In Germany, a companion external validation study 
(ALIVAL) of the ICD discharge and outpatient diagnosis 
codes for ALI was conducted in a German hospital to esti-
mate the PPV of algorithms used in the GePaRD data source 
to identify potential cases of the primary and tertiary end-
points. In Sweden, no validation of cases was implemented.
In the case–control analysis, all ALI cases identified 
according to the definition of each endpoint in the study 
cohort were included as cases. Controls were selected from 
the study cohort using density sampling. Up to 20 controls 
per case were randomly selected from the risk set of each 
case. Controls were matched to cases on age and sex, index 
date, and calendar year of study (cohort) entry.
2.5  Exposure Variables and Confounding Factors
Time at risk was defined according to the days of supply of 
each prescription fill plus a period of 40 days. Days of sup-
ply were the assumed number of days of treatment associ-
ated with each prescription fill. The period of 40 days was 
added to account for stockpiling and less than perfect adher-
ence [34].
1 The terms “specific” and “nonspecific” are used here to indicate 
groups of codes that have in previous studies showed more (specific) 
or less (nonspecific) positive predictive values for ALI.
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In the nested case–control main analysis, use status was 
classified for each patient and each antidepressant into four 
mutually exclusive categories according to time at risk of 
the most recent prescription fill received on or before the 
index date:
• Current use: when the time at risk of the most recent 
prescription fill overlapped the index date
• Recent use: when the time at risk ended within 60 days 
before the index date
• Past use: when the time at risk ended more than 60 days 
before the index date
• Nonuse: when there was no prescription fill of the study 
drug under consideration before the index date
Confounding factors were those related to the risk of ALI 
[13, 14, 35] and to exposure to agomelatine or another study 
antidepressant. Age, sex, and year of entrance in the cohort 
(through matching); acute alcohol intoxication; obesity; 
other components of metabolic syndrome (hypertension and 
dyslipidaemia); diabetes; inflammatory bowel disease; pre-
existing comorbidity measured by the Charlson Comorbid-
ity Index; acute biliary and pancreatic disease; peptic ulcer 
disease; rheumatic diseases; concurrent use of hepatotoxic 
drugs (list of drugs available in Online Resource 4; see the 
electronic supplementary material); concurrent use of other 
antidepressants (different from study antidepressants); num-
ber of liver tests performed; and health care resource utili-
zation measures were considered potential risk factors or 
confounders.
2.6  Statistical Analyses
Crude and adjusted odds ratios (ORs) and 95% confidence 
intervals (CIs) for ALI for current use of each study antide-
pressant were estimated using conditional logistic regres-
sion models, with current use of citalopram as the reference 
category (main analysis).
Crude ORs (and 95% CIs) were estimated including only 
the exposure variables in the conditional logistic regression 
model. Due to the matching of cases and controls and con-
ditional analyses, these crude ORs were adjusted by age, 
sex, and calendar year at study entry, but were referred to as 
crude ORs regarding the rest of the confounders. Because of 
the low number of cases in some data sources, the original 
exposure variables had to be reclassified into fewer catego-
ries (i.e. current use vs. other), and in each of the separate 
logistical models comparing citalopram with each one of the 
other antidepressants, a new single exposure variable was 
created to classify current use status of the two antidepres-
sants being compared.
Important risk factors and potential confounders were a 
priori included in the models. Other potential confounders 
were tested in a backward elimination process [36] to avoid 
problems with zero cells in the analysis. In the nested 
case–control analysis, presence of risk factors and con-
founders was evaluated at any time before the index date, 
but some variables (e.g. concurrent use of hepatotoxic 
drugs) were evaluated just 6 months before the index date. In 
Online Resource 5, we include a table providing additional 
details on the timing of evaluation for the different potential 
confounders.
For each of the three study endpoints, meta-analysis was 
used to combine the adjusted OR estimates obtained from 
the nested case–control analysis in the different data sources. 
Combined ORs and 95% CIs for ALI were produced first 
using random-effects models [37]. To assess heterogeneity 
in the meta-analysis, the I2 statistic was employed. When 
results were homogeneous across databases, fixed-effects 
models were used, and these results were presented in the 
results tables. When the I2 test statistic was 30% or higher 
for any of the antidepressants, random-effects models were 
presented for all antidepressants. Forest plots were created 
for each analysis table to display the adjusted combined and 
data source–specific results. When no events were observed 
in some of the data sources, we included only the results 
from data sources with observed events.
To check the robustness of the results, several planned 
sensitivity analyses were performed: the effect of adding 
15 days or 60 days (instead of 40 days) to the days of supply 
of the most recent prescription before the index date was 
explored; the effect of recent and past use of each study 
antidepressant was compared with current use of citalopram; 
switching and multiple current use were compared with cur-
rent single use of citalopram; and analyses restricted to cases 
without known causes of ALI were conducted. The imple-
mentation of those sensitivity analyses was limited in most 
data sources by the limited number of cases. In addition, 
two post hoc sensitivity analyses recommended by regula-
tory reviewers were implemented for the primary endpoint. 
In one, no exclusion criteria were implemented, and in the 
other, all study exclusion criteria were applied except those 
related to alcohol use disorder and drug abuse.
3  Results
A total of 3,238,495 new users of antidepressants (Epi-
Chron, n = 185,628; SIDIAP, n = 203,101; the GePaRD, 
n = 817,072; the Danish National Health Registers, 
n = 664,205; and the Swedish National Registers in Swe-
den, n = 1,368,489) were included in the main analysis, of 
which 74,440 were new users of agomelatine (Table 1). 
Agomelatine, the most recently launched of the studied 
antidepressants, was the least dispensed antidepressant in 
the study. A table presenting the distribution of the main 
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confounder factors at cohort entry in each data source is 
included in Online Resource 6 (see the electronic supple-
mentary material).
In the main analysis, a total of 472 cases were identified 
for the ALI primary endpoint (specific hospital discharge 
codes), ranging from 19 (SIDIAP) to 170 (Danish National 
Health Registers). Online Resource 7 presents the number 
of cases and controls in each data source and the association 
between potential confounders and the ALI primary end-
point in the multivariable adjusted models, which was dif-
ferent in the five data sources. Table 2 displays the number 
of new users in each antidepressant cohort and the number 
of cases and controls by endpoint, antidepressant cohort, 
and overall numbers.
3.1  Primary Endpoint
Online Resource 8 presents the age- and sex-standardised 
incidence rates of ALI for the primary endpoint by data 
source and studied antidepressant. The estimates were 
imprecise, ranged from 0 to 27 cases per 100,000 person-
years, and were overall within the range of the ALI incidence 
rates described previously in the literature [38]. The PPVs 
for the specific codes used to identify the primary endpoint 
ranged from 60.0% (SIDIAP) to 84.2% (EpiChron) in the 
study data sources, and the PPV was 62.7% in the external 
validation study in Germany (ALIVAL).
Results of the case–control analyses for the current use 
of agomelatine compared with current use of citalopram are 
presented in Table 3.
Current use of agomelatine compared with current use 
of citalopram yielded ORs below 1.00 in all data sources 
with cases (no cases under current use of agomelatine were 
identified in SIDIAP and Sweden) with imprecise estimates. 
The combined (meta-analysis) adjusted OR for current use 
of agomelatine compared with citalopram was 0.48 (95% CI 
0.13–1.71).
In the post hoc sensitivity analysis without exclusions 
(including 4,833,774 new users of antidepressants, of which 
117,240 were new users of agomelatine), more cases were 
identified, and therefore, the OR estimates were more precise 
and in line with the main analysis. The combined adjusted 
OR for current use of agomelatine compared with citalo-
pram was 0.37 (95% CI 0.19–0.74). The point estimates 
were homogeneous across all data sources for the sensitiv-
ity analysis without exclusions.
In the post hoc sensitivity analysis including patients with 
disorders related to alcohol and drug abuse (3,531,529 new 
users of antidepressants, of which 84,210 were new users of 
agomelatine), the combined adjusted OR for current use of 
agomelatine compared with citalopram was 0.47 (95% CI 
Table 2  Number of new users in each antidepressant cohort and number of cases and controls by study endpoint and antidepressant cohort
Percentages in each cell were obtained from the total number of ALI cases or controls included in the column header
Due to data protection policies, the exact number of cases could not be provided when the number of cases was less than 5
ALI acute liver injury
a Percentages in this column are row percentages of the total number of all users
b This number represents the total number of ALI cases. Cases in the body of the table are only those identified among current users
c This number represents the total number of controls. Controls in the body of the table are only those with current use of the antidepressant
New users, 
N (%)a
[n = 3,238,495]
Primary endpoint (specific hospital 
discharge codes)
Secondary endpoint (specific 
and non-specific hospital 
discharge codes—only validated 
cases included)
Tertiary endpoint (specific and 
non-specific hospital discharge and 
outpatient codes)
Number of  casesb 
(%)
[n = 472]
Number of 
 controlsc (%)
[n = 9438]
Number of  casesb 
(%)
[n = 178]
Number of 
 controlsc (%)
[n = 3540]
Number of  casesb 
(%)
[n = 17,118]
Number of 
 controlsc (%)
[n = 342,070]
Citalopram 782,812 (24.2%) 111 (23.5%) 1790 (19.0%) 45 (25.3%) 806 (22.8%) 2667 (15.6%) 53,296 (15.6%)
Agomelatine 74,440 (2.3%) 2 (0.4%) 112 (1.2%) n < 5 59 (1.7%) 284 (1.7%) 4771 (1.4%)
Fluoxetine 150,569 (4.6%) 9 (1.9%) 217 (2.3%) n < 5 51 (1.4%) 547 (3.2%) 10,974 (3.2%)
Paroxetine 125,595 (3.9%) 7 (1.5%) 201 (2.1%) 1 (0.6%) 72 (2.0%) 590 (3.4%) 10,853 (3.2%)
Sertraline 479,631 (14.8%) 41 (8.7%) 805 (8.5%) 13 (7.3%) 314 (8.9%) 775 (4.5%) 15,412 (4.5%)
Escitalopram 260,367 (8.0%) 25 (5.3%) 490 (5.2%) 16 (9.0%) 255 (7.2%) 603 (3.5%) 12,902 (3.8%)
Mirtazapine 556,888 (17.2%) 41 (8.7%) 967 (10.2%) 18 (10.1%) 458 (12.9%) 1348 (7.9%) 23,433 (6.9%)
Venlafaxine 271,032 (8.4%) 35 (7.4%) 637 (6.7%) 7 (3.9%) 254 (7.2%) 1178 (6.9%) 19,900 (5.8%)
Duloxetine 158,686 (4.9%) 11 (2.3%) 322 (3.4%) 2 (1.1%) 122 (3.4%) 502 (2.9%) 9297 (2.7%)
Amitriptyline 378,475 (11.7%) 22 (4.7%) 467 (4.9%) 3 (1.7%) 125 (3.5%) 1084 (6.3%) 17,644 (5.2%)
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0.20–1.07). The individual point estimates from the differ-
ent data sources were less homogeneous: both EpiChron 
and SIDIAP, which had the smallest agomelatine cohorts, 
showed OR estimates above 1.00 with wide 95% CIs.
Figure 1 presents the combined results for current use of 
each antidepressant in the main analysis and the two post hoc 
sensitivity analyses for the primary endpoint. For all anti-
depressants except fluoxetine and paroxetine, the combined 
point estimates were less than 1.00 in the main analysis. The 
95% CIs were more imprecise in the main analysis than in 
the two post hoc sensitivity analyses, in which all antidepres-
sants had ORs below 1.00 when compared with citalopram.
Results of the planned sensitivity analyses (including the 
ones assessing different exposure definitions and analysis 
excluding known causes of ALI) for agomelatine and the 
other antidepressants were, in general, consistent with the 
main analysis and produced combined OR point estimates 
for agomelatine below 1.00 for current use (data not shown). 
Results for all antidepressants, combined and in each indi-
vidual data source, and for the three endpoints are available 
in the electronic supplementary material (Online Resources 
9–11).
3.2  Secondary Endpoint
The secondary endpoint included only cases that had been 
confirmed after validation, which resulted in a lower num-
ber of events than for the primary endpoint. A total of 178 
confirmed cases (150 in Denmark, 20 in EpiChron, eight 
in SIDIAP) and 3540 controls were identified. Confirmed 
cases during current use of agomelatine were identified in 
Denmark only; the adjusted OR estimate for current use 
was 0.40 (95% CI 0.05–3.11). For the other antidepressants 
when compared with citalopram, most combined OR point 
estimates were less than one, except that of fluoxetine. The 
estimates were imprecise (Online Resource 10).
3.3  Tertiary Endpoint
Overall, there were 17,118 cases of the tertiary study end-
point and 342,070 controls. The GePaRD had overall the 
largest number of cases (11,917), followed by SIDIAP 
(2826), Sweden (1099), Denmark (1088), and EpiChron 
(268). The PPV of the tertiary endpoint cases was low in all 
data sources, but especially in SIDIAP (7.7%). The high-
est PPVs (47.0%) were found in Denmark and the ALIVAL 
external study (Germany, 45.1%). In EpiChron, the PPV was 
25.4%. In Sweden, no validation of cases was implemented.
For this tertiary endpoint, the combined estimate for 
agomelatine for current use was 0.79 (95% CI 0.50–1.25). 
The results were heterogeneous (I2 = 71%, indicating 
the presence of strong heterogeneity). The individual 
data source–adjusted ORs for current use of agomelatine 
were also below 1.00, except in the GePaRD, and ranged 
from 0.36 (95% CI 0.11–1.25) in Sweden to 0.95 (95% 
CI 0.33–2.75) in EpiChron. In the GePaRD, the adjusted 
OR was 1.24 (95%  CI 1.07–1.42) and contrasted with 
the ORs observed in Denmark and Sweden, which were 
approximately 0.5 (Online Resource 12). In Denmark, the 
adjusted OR estimate for current use of agomelatine was 
0.44 (95% CI 0.22–0.87). In the sensitivity analysis that 
included only confirmed cases (confirmed cases available 
Table 3  Results for the primary endpoint and current use (agomelatine vs. citalopram) in each data source and combined in the main analysis 
and the two post hoc sensitivity  analysesa
CI confidence interval, GePaRD German Pharmacoepidemiological Research Database, OR odds ratio, SIDIAP Information System for 
Research in Primary Care
a Adjusted for confounding factors; the list of confounders differed by data source. The following confounders were included in most analyses: 
obesity, hyperlipidaemia and hypertriglyceridaemia, diabetes, hypertension, indication of treatment with antidepressants for major depression, 
indication of treatment with antidepressants for anxiety disorders, indication of treatment with antidepressants for other mental and behavioural 
disorders, Charlson Comorbidity Index, number of liver tests performed, concurrent use of hepatotoxic drugs, and concurrent use of other anti-
depressants
b“ –” indicates that the model did not converge
EpiChron
OR (95% CI)
SIDIAP
OR (95% CI)
GePaRD
OR (95% CI)
Danish National 
Health Registers
OR (95% CI)
Swedish National 
Registers
OR (95% CI)
Combined
OR (95% CI)
Primary endpoint (specific codes, hospitalised patients)
 Main  analysisb 0.82 (0.06–10.70) – 0.55 (0.06–4.72) 0.30 (0.04–2.32) – 0.48 (0.13–1.71)
Sensitivity post hoc analyses
 No exclusion criteria 
applied
0.66 (0.06–7.16) 0.61 (0.08–4.87) 0.36 (0.10–1.39) 0.32 (0.12–0.84) 0.26 (0.01–8.17) 0.37 (0.19–0.74)
 Exclusion criteria 
applied, except alco-
hol and drug abuse
1.60 (0.12–21.33) 1.43 (0.15–13.84) 0.51 (0.08–3.03) 0.30 (0.09–1.00) 0.16 (0.01–3.85) 0.47 (0.20–1.07)
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Main analyses Ep = EpiChron
Sd = SIDIAP
G = GePaRD
Dk = Denmark
Sw = Sweden
No exclusion criteria 
applied
Exclusion criteria applied, 
except alcohol and drugs
Citalopram
Sertraline
Escitalopram
Mirtazapine
Duloxetine
Venlafaxine
Paroxetine
Fluoxetine
Agomelatine
Amitriptyline
Controls
1,790
7,096
2,870
112
518
202
217
933
434
201
912
370
805
3,375
1,361
490
2,180
875
967
4,158
1,643
637
2,603
1,121
322
1,433
563
467
1,847
673
Cases
111
418
168
2
7
5
9
41
23
7
39
12
41
137
69
25
110
44
41
233
87
35
132
66
11
62
31
22
95
30
Data sources
included
Ep, G, Dk
Ep, Sd, G, Dk, Sw
Ep, Sd, G, Dk, Sw
Ep, G, Dk, Sw
Ep, Sd, G, Dk, Sw
Ep, Sd, G, Dk, Sw
Ep, Sd, G, Dk
Ep, Sd, G, Dk, Sw
Ep, Sd, G, Dk, Sw
Ep, Sd, G, Dk, Sw
Ep, Sd, G, Dk, Sw
Ep, Sd, G, Dk, Sw
Ep, Sd, G, Dk, Sw
Ep, Sd, G, Dk, Sw
Ep, Sd, G, Dk, Sw
Ep, Sd, G, Dk, Sw
Ep, Sd, G, Dk, Sw
Ep, Sd, G, Dk, Sw
Ep, Sd, G, Dk, Sw
Ep, Sd, G, Dk, Sw
Ep, Sd, G, Dk, Sw
Ep, G, Dk, Sw
Ep, Sd, G, Dk, Sw
Ep, G, Dk, Sw
Ep, Sd, G, Dk, Sw
Ep, Sd, G, Dk, Sw
Ep, Sd, G, Dk, Sw
I2
0%
0%
0%
0%
36%
34%
0%
0%
31%
0%
0%
0%
0%
0%
0%
0%
32%
0%
7%
0%
28%
0%
42%
2%
54%
46%
68%
Odds ratio (95% CI)
0.48 (0.13-1.71)
(Reference)
0.37 (0.19-0.74)
0.47 (0.20-1.07)
1.07 (0.52-2.21)
0.63 (0.32-1.25)
0.89 (0.43-1.82)
1.29 (0.65-2.57)
0.70 (0.44-1.12)
0.88 (0.41-1.90)
0.88 (0.58-1.34)
0.65 (0.49-0.85)
0.82 (0.59-1.15)
0.80 (0.45-1.40)
0.80 (0.58-1.09)
0.82 (0.53-1.26)
0.69 (0.45-1.05)
0.85 (0.61-1.20)
0.83 (0.60-1.14)
0.89 (0.55-1.44)
0.78 (0.59-1.03)
0.81 (0.49-1.36)
0.60 (0.31-1.16)
0.71 (0.39-1.28)
0.80 (0.48-1.33)
0.55 (0.22-1.41)
0.83 (0.50-1.38)
0.71 (0.28-1.76)
Drugs for 
depression
Favours comparator 
(citalopram)
Favours other study
drugs for depression
0.0 0.5 1.0 1.5 2.0 3.02.5
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only in Denmark; see Online Resources 13) of the tertiary 
endpoint, the OR was 0.75 (95% CI 0.17–3.22).
For the other antidepressants (Online Resource 11), 
all combined OR estimates were between 0.94 and 1.11. 
There was an indication of heterogeneity for mirtazapine, 
duloxetine, and amitriptyline (I2 > 50%, indicating at least 
moderate heterogeneity). The combined OR 95% CIs of 
the tertiary endpoint were more precise than for the other 
two endpoints. In the sensitivity analysis that included only 
confirmed cases (Online Resource 13), all combined OR 
estimates were below one except for duloxetine (OR 1.03; 
95% CI 0.60–1.79).
4  Discussion
Use of agomelatine was not associated with higher risk of 
ALI hospitalisation compared with use of citalopram in a 
large cohort comprising 3.2 million new users of antide-
pressants in five populations from four countries: Spain, 
Denmark, Sweden, and Germany. Although precision of the 
combined risk estimates was low for the primary endpoint, 
the results were similar and more precise in the unrestricted 
sensitivity analyses and consistent both with the other sen-
sitivity analyses and with the results of the other two end-
points considered. In the combined analysis, no increase in 
risk was observed in populations including alcoholic patients 
or patients with other various risk factors. For the other anti-
depressants, most presented ORs below 1, except for fluox-
etine and paroxetine. Further, as for agomelatine, similar 
results were obtained when using other outcome definitions, 
that is, the secondary and tertiary endpoints.
The estimates of risk associated with agomelatine use 
in this study are consistent with those from a recent cohort 
study funded by the French National Agency for Medi-
cines and Health Products Safety and conducted using the 
French health insurance database. This study did not find 
an increased risk of severe liver injury associated with the 
use of agomelatine compared with use of selective serotonin 
reuptake inhibitors (adjusted hazard ratio 1.07; 95% CI 
0.51–2.23) [39].
In our study, analyses of most study antidepressants 
yielded ORs of ALI hospitalisation lower than 1.00 when 
compared with citalopram in the combined analyses for all 
endpoints. Since we had no pre-suspicion that citalopram 
would carry a particularly high risk of ALI, the consistency 
in the direction of this association across antidepressants 
was unexpected. However, the limitations discussed here-
after, particularly those related to the low number of cases, 
preclude drawing definite conclusions. Citalopram is, in 
many countries, one of the first-line treatment options and 
is considered one of the safest antidepressants and could 
be selectively prescribed to those cases at the highest risk 
of ALI, which could potentially result in confounding by 
indication, but other antidepressants in this study share a 
similar drug prescription pattern. Although citalopram has 
been considered safe when compared with other antidepres-
sants in analyses of spontaneous reports of adverse drug 
reactions [40, 41] and in reviews of published clinical data 
[3], two epidemiological studies found an increased risk of 
drug-induced liver injury associated with citalopram use 
[42, 43]. Of note, the French study [39] did not find any 
relevant differences in risk between selective serotonin reup-
take inhibitors, serotonin and noradrenaline reuptake inhibi-
tors, and other antidepressants (e.g. agomelatine).
As in any study in automated data, misclassification 
of exposure status, occurrence of incident events, and the 
covariates to be included in the multivariable models is 
possible. In this study, this would likely have resulted in 
nondifferential misclassification of the endpoints, potentially 
biasing the estimates towards unity. However, small differ-
ences in misclassification of the exposure or the disease may 
result in bias towards or away from unity in an unpredictable 
manner [44].
To minimise misclassification of endpoints, specific 
codes were used for the primary endpoint, and validation 
of the secondary endpoint that included nonspecific codes 
was implemented. Validation of potential cases was imple-
mented in a sensitivity analysis of the tertiary endpoint. 
The sources and the quantity of information available dif-
fered across data sources and the underlying health care 
systems (e.g. body mass index was available in data sources 
with access to primary care data), which may explain some 
of the differences observed in the prevalence of some clini-
cal features, as well as the differences observed across the 
study data sources in the PPVs and some OR estimates. 
For the primary endpoint, the PPVs of the specific codes 
ranged from 60% in SIDIAP to 84% in EpiChron and were 
consistent or higher than the estimates from previous stud-
ies [45–52]. In SIDIAP, access to hospital medical records 
was not available, and PPVs would have probably been 
higher otherwise. Some PPV estimates were imprecise, 
Fig. 1  Current use combined adjusted estimates for all antidepres-
sants (primary endpoint main and two sensitivity post hoc analyses 
removing exclusion conditions). Odds ratio estimates were adjusted 
for confounding factors. The list of confounders differed by data 
source and type of analysis (main vs. sensitive analyses). The follow-
ing confounders were included in most analyses: obesity, hyperlipi-
daemia and hypertriglyceridaemia, diabetes, hypertension, indication 
of treatment with antidepressants for major depression, indication of 
treatment with antidepressants for anxiety disorders, indication of 
treatment with antidepressants for other mental and behavioural dis-
orders, Charlson Comorbidity Index, number of liver tests performed, 
concurrent use of hepatotoxic drugs, and concurrent use of other anti-
depressants. CI confidence interval, GePaRD German Pharmacoepi-
demiological Research Database, SIDIAP Information System for 
Research in Primary Care
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especially in SIDIAP and in the ALIVAL study, and dif-
ferences between data sources could be also explained by 
random error. Importantly, however, the results of the sec-
ondary endpoint that included only confirmed cases were 
consistent with the results of the primary endpoint.
As already mentioned, the number of identified events 
of the primary and secondary endpoint was limited among 
agomelatine users and users of other antidepressants. For 
the tertiary endpoint, the number of cases was much higher 
(especially in the GePaRD and SIDIAP), yet the low PPVs 
observed for this endpoint definition limit the interpretation of 
these results in the analysis that included unconfirmed cases.
Patients taking agomelatine undergo routine liver enzyme 
monitoring as a risk minimisation measure. Therefore, 
patients at known risk of developing ALI may not have been 
prescribed agents (such as agomelatine) that are thought to be 
associated with an increased risk of ALI. Moreover, detection 
of liver enzyme elevations may be more likely in this group 
and prevent patients from starting treatment with agomelatine, 
or if agomelatine treatment has been started, treatment may be 
stopped earlier or cases of liver injury may be detected more 
frequently and earlier than if liver enzyme monitoring had not 
been conducted. In the context of observational studies using 
data from routine clinical practice, these scenarios could lead 
to selective prescribing, surveillance bias, or both. Selective 
prescribing, i.e. the less frequent prescription of agomelatine 
to patients with known risk factors for ALI or with evidence of 
existing liver damage measured by liver function tests, would 
shift the results in favour of agomelatine and lead to an appar-
ently lower risk of ALI among agomelatine new users when 
compared with new users of citalopram. The comparison of 
the different antidepressant cohorts in the main analysis and in 
the sensitivity analysis including patients with known risk fac-
tors (data not shown) do not seem to indicate that agomelatine 
is less prescribed among patients with known risk factors (e.g. 
chronic liver conditions). Moreover, the results of the sensitiv-
ity analysis are consistent with the results of the main analysis, 
the latter excluding patients at risk of ALI, and show an OR 
estimate also below one and with larger precision. However, 
because of the risk minimisation measures in place, selective 
prescribing could still take place (e.g. agomelatine would not 
be prescribed to those patients with abnormal liver tests or 
those with contraindications and precautions of use accord-
ing to approved label), and this cannot be assessed with the 
data available. Thus, it is plausible that selective prescribing 
may have influenced the results of the study, which need to be 
interpreted in the context of the risk minimisation measures in 
place for agomelatine. In fact, our results suggest that the risk 
minimization measures in place for agomelatine are effective.
Similarly, surveillance bias is unlikely to have had a large 
impact on the reported estimates for the primary and sec-
ondary endpoints, as these included only hospitalised and 
thereby more severe cases. In the combined results, no risk 
increase was found for the tertiary endpoint, which was in 
principle more sensitive to surveillance bias and misclassi-
fication than the primary and secondary endpoints. Surveil-
lance bias would have resulted in ORs above 1.00. However, 
in the context of low PPVs, nondifferential misclassification 
would produce bias towards seeing no association.
The possibility of residual confounding cannot be dis-
carded. As mentioned, the amount of information on some 
potential confounders (e.g. obesity) was limited in some of 
the data sources. Moreover, the limited number of identified 
ALI cases for the primary and secondary endpoints impacted 
the multivariable logistic regression strategy. To ensure a 
sufficient case-to-covariate ratio, the number of covariates 
and number of categories for categorical covariates included 
in the models had to be minimised. This resulted in more 
statistically stable models, but it may have increased the risk 
of residual confounding. Nevertheless, the restrictive cohort 
inclusion criteria implemented likely excluded most of the 
key potential confounders associated with ALI. Moreover, 
the post hoc analysis that did not impose any exclusion 
criteria resulted in a much larger number of new users of 
agomelatine (117,240) and of other antidepressants (4.8 mil-
lion overall) and yielded more precise OR estimates for the 
primary endpoint that were consistent with those obtained in 
the main analysis. Also, control of confounding via multivar-
iable models in those analyses did not have the limitations 
encountered in the main analysis of the primary endpoint.
The study had important strengths, first of which is that it 
evaluated more than 3 million (almost 5 million in one of the 
sensitivity analyses) new users of antidepressants and is the 
first study of this size to include also a validation component 
of the cases identified. Second, inclusion of multiple inde-
pendent data sources and populations from different countries 
allowed evaluation of the consistency of the findings across 
five different, heterogeneous, automated, health care data 
sources. Finally, including three different endpoints with vari-
ous degrees of PPV and yielding a varying number of cases 
created different perspectives for interpreting the study results.
5  Conclusion
The results of this study do not suggest that risk of hospital-
ised ALI with use of agomelatine (compared with use of cit-
alopram) constitutes a public health problem, at least among 
patient populations in health care systems with prescription 
patterns and risk minimisation measures similar to those in 
this study. Thus, it is important to keep in place and comply 
with the existing risk minimisation measures for agomela-
tine, which our results suggest are effective in preventing 
ALI among users of agomelatine. When compared with 
citalopram, most antidepressants had OR point estimates 
less than 1.00 for hospitalised ALI. However, uncontrolled 
Risk of Acute Liver Injury in New Users of Agomelatine and Other Antidepressants
sources of bias could explain the results, and specific studies 
to investigate this potential association of citalopram with 
ALI are needed.
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